Qpex Biopharma, Inc., part of the Shionogi Group, announced a leadership transition with Gareth Morgan, MS, MBA, stepping in as the new President. Morgan most recently held the position of Senior Vice President and Global Head of Portfolio Management and AMR Policy at Shionogi Inc. He takes over from Michael Dudley, Pharm.D., who has officially retired from his role as President and CEO. While stepping down, Dr. Dudley will continue supporting both Qpex and Shionogi as a strategic advisor.
Health Technology Insights: QuantHealth Gains Sanofi Ventures Investment for AI Trials
Shionogi Inc., the U.S. subsidiary of Japan-based Shionogi & Co., Ltd., acquired Qpex in 2023. This acquisition brought Qpex’s scientific expertise in antibiotic development and added an innovative pipeline of drug candidates, including a beta-lactamase inhibitor currently under investigation. The deal has expanded Shionogi’s reach in anti-infective research and development, strengthening its global drug discovery capabilities.
Reflecting on his time leading Qpex, Dr. Dudley expressed pride in the company’s growth and evolution. He shared that guiding Qpex from its early days into becoming part of Shionogi’s global network has been a rewarding journey. He noted his confidence in Morgan’s leadership, highlighting his strong background in anti-infective drug development and deep experience working within Shionogi. Dudley also pointed out Morgan’s success in forging key relationships with governments and international organizations, which he believes will help elevate Qpex in the next phase of its mission.
Health Technology Insights: Humana’s 2026 Medicare Advantage Plans Focus on Quality Care
Before joining Shionogi in 2007, Gareth Morgan held various leadership roles in clinical development and project management at major pharmaceutical companies. His work involved managing global registration studies in several therapeutic areas. At Shionogi, he played a key role in advancing the company’s siderophore cephalosporin discovery program. Morgan has also led high-impact public-private partnerships and was behind a notable technology transfer agreement with the Global Antibiotic Research and Development Partnership, as well as a collaboration with the Clinton Health Access Initiative to improve antibiotic access in underserved countries.
In accepting his new position, Morgan praised Dudley’s legacy and the foundation he helped build at Qpex. He described Dudley as a visionary who transformed Qpex from a startup into a thriving research organization. Morgan expressed his gratitude for the opportunity to lead and said he looks forward to working with the Qpex team to continue advancing life-saving treatments. He emphasized that although Dudley is stepping away from day-to-day operations, his influence and entrepreneurial mindset will remain a guiding force within the company.
Health Technology Insights: InteropKey and Corista Unite for Value-Based Care Growth
To participate in our interviews, please write to our HealthTech Media Room at sudipto@intentamplify.com
Source – businesswire
